MENU

INZY Stock Inozyme Pharma (INZY, $2.98) entered Uptrend as Momentum indicator ascends above 0 level on Dec 10, 2024

A.I.dvisor
at Tickeron.com
Loading...
INZY - Inozyme Pharma
Momentum signal
Bullish Trend
Odds of UP Trend
Tickeron
Momentum signal
Price: $2.98
Daily change: +$0.26 (+9.56%)
Daily volume: 1.1M
Industry: Biotechnology
This indicator may be signaling that INZY's price has momentum to move higher, since its current price exceeds the price logged 14 days ago. Traders may consider buying the stock or exploring call options. A.I.dvisor backtested 88 similar cases where INZY's Momentum Indicator exceeded 0, and of them led to a successful outcome. Odds of Success:

INZY in +2.37% Uptrend, advancing for three consecutive days on December 13, 2024

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where INZY advanced for three days, in of 228 cases, the price rose further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where INZY's RSI Indicator exited the oversold zone, of 31 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on December 10, 2024. You may want to consider a long position or call options on INZY as a result. In of 88 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for INZY just turned positive on December 02, 2024. Looking at past instances where INZY's MACD turned positive, the stock continued to rise in of 48 cases over the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 50 cases where INZY's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where INZY declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

INZY broke above its upper Bollinger Band on December 10, 2024. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for INZY entered a downward trend on December 17, 2024. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.282) is normal, around the industry mean (14.664). P/E Ratio (0.000) is within average values for comparable stocks, (87.689). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.783). INZY has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.012). P/S Ratio (0.000) is also within normal values, averaging (260.687).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. INZY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. INZY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
INZY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a company, which engages in the research and development of pharmaceutical products

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
321 Summer Street
Phone
+1 857 330-4340
Employees
59
Web
https://www.inozyme.com